Additionally, the 36-month beta value for SNWV is 1.19. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SNWV is 7.83M and currently, short sellers hold a 0.61% ratio of that float. The average trading volume of SNWV on June 20, 2025 was 55.23K shares.
SNWV) stock’s latest price update
Sanuwave Health Inc (NASDAQ: SNWV)’s stock price has increased by 10.40 compared to its previous closing price of 29.89. However, the company has seen a 5.20% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-11 that Sanuwave’s UltraMIST offers superior wound care, reducing costs and healing time for hospitals, making it attractive to both providers and insurers. Under new CEO Morgan Frank, Sanuwave has revitalized growth, improved margins, and uplisted to Nasdaq, with the stock price quadrupling since his appointment. Revenue growth is robust, recurring consumables sales strengthen the business model, and the company is on track to triple manufacturing capacity.
SNWV’s Market Performance
Sanuwave Health Inc (SNWV) has experienced a 5.20% rise in stock performance for the past week, with a 11.56% rise in the past month, and a 4.07% rise in the past quarter. The volatility ratio for the week is 6.72%, and the volatility levels for the past 30 days are at 4.80% for SNWV. The simple moving average for the past 20 days is 13.26% for SNWV’s stock, with a 39.77% simple moving average for the past 200 days.
SNWV Trading at 11.29% from the 50-Day Moving Average
After a stumble in the market that brought SNWV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.46% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNWV starting from Stegagno Peter, who sale 1,862 shares at the price of $27.71 back on Jun 05 ’25. After this action, Stegagno Peter now owns 2,032 shares of Sanuwave Health Inc, valued at $51,596 using the latest closing price.
Cioanta Iulian, the Chief Sci. and Tech. Officer of Sanuwave Health Inc, sale 3,639 shares at $31.60 during a trade that took place back on May 15 ’25, which means that Cioanta Iulian is holding 41 shares at $114,992 based on the most recent closing price.
Stock Fundamentals for SNWV
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.77 for the gross margin
The net margin for Sanuwave Health Inc stands at -0.9. The total capital return value is set at -0.45.
Based on Sanuwave Health Inc (SNWV), the company’s capital structure generated -0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -0.2. The debt to equity ratio resting at -0.05. The interest coverage ratio of the stock is 0.91.
Currently, EBITDA for the company is -16.56 million with net debt to EBITDA at 1.88. When we switch over and look at the enterprise to sales, we see a ratio of 7.59. The receivables turnover for the company is 9.36for trailing twelve months and the total asset turnover is 1.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
In conclusion, Sanuwave Health Inc (SNWV) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
